Chiglitazar Sodium

西格列他钠

Report date: 2023/11/17 15:57:01
NME

Base Information

Drug NameChiglitazar Sodium
Drug Alias Name西格列羧Carfloglitazar西格列他Carfloglitazar sodium (Chipscreen Biosciences)Bilopine/Bilessglu +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor α agonistsPeroxisome proliferator-activated receptor γ agonistsPeroxisome proliferator-activated receptor delta agonists
TargetsPeroxisome proliferator-activated receptor αPeroxisome proliferator-activated receptor γPeroxisome proliferator-activated receptor delta
Therapy Area/IndicationsInsulin ResistanceDiabetes Mellitus, Type 2Diabetes Mellitus +[6] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2021/10/19
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShenzhen Chipscreen Biosciences Co LtdChipscreen Biosciences Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesZhejiang Hisun Pharmaceutical Co LtdChengdu Chipscreen Pharmaceutical Co LtdShenzhen Chipscreen Biosciences Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsInsulin ResistanceDiabetes Mellitus, Type 2Renal Insufficiency +[5] 
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeA10BX
Related LinksN/A